BAY1161909

pro-mitotic selective MPS1 kinase inhibitor

dev. paused for 2nd candidate (BAY1217389)

from 2M cmpd biochem. HTS and SBDD

J. Med. Chem., Apr. 27, 2020

Bayer AG, Berlin, DE

BAY1161909 is one of two clinical candidates disclosed in a single paper from Bayer. The compounds have an interesting anti-cancer mechanism – rather than inhibiting cancer cell growth, they accelerate…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks